However, in contrast to our findings, Venken K et al. [55] showed that patients with RR-MS had reduced Foxp3 expression level and lower numbers of circulating CD4+ CD25high Foxp3+ T cells compared with SP-MS patients. This evidence concerns the gene CD4 and myeloid sarcoma.